A number of nucleoside mono-and diphosphites and phosphonates containing 1,2-dicarbadodecaborane (12) (la-6b) at 5'-position of the sugar moiety have been synthesized in good yields. Experimental details along with the spectroscopic and analytical data, supporting the formation of the title compounds, are presented. These constitute a new generation of boron compounds that are envisioned to be useful in cancer treatment via Boron Neutron Capture Therapy (BNCT).
INTRODUCTION
The concept of BNCT was first proposed by Locher some sixty years ago/l/. However, the successful application of BNCT for the treatment of cancer still presents a challenge in medical research. Over the last decade or so, various boron-containing analogues of biologically active compounds such as amino acids/2/, peptides/3/, porphyrins/4/, polyamines/5/, nucleosides, as well as DNA binders/6/, have been synthesized and evaluated for their possible use in BNCT. Such analogues might function in a manner similar to their naturally occurring counterparts and become selectively incorporated into either proliferating or more metabolically active tumor cells. The requirement of 25-30/zg of B atoms per gram of tumor for effective BNCT/7/has led researchers to incorporate 1, 2-dicarbadodecaborane (o-carborane) as the integral part of many cancer drugs/8/. The C2B10 carborane cage has unique electronic and steric properties that also make it an intriguing moiety in drug design/9/. Boron containing nucleosides are potentially attractive because they should be (1) taken up selectively into tumor due to high mitotic rate of tumor cells vs. normal cells, (2) intra-cellularly converted to the corresponding nucleotides by phosphorylation, and (3) incorporated into tumor DNA, thereby enhancing the cytotoxicity of neutron capture therapy/10/. Early work focused on the development and synthesis of boron-containing purine and pyrimidine bases in which the boron atom was placed within the purine or pyrimidine nucleus and flanked by two nitrogen atoms /1 l/. Several boron containing nucleosides have also been synthesized with a borane, cyanoborane, dihydroxylboryl, and (3) were prepared by the methods described elsewhere/14/. 1,2-Bis(chioromethylphosphate)-l,2-dicarbadodecaborane (4), l-phenyl-2-(chloromethylphosphate)-1,2-dicarbadodecaborane (5), I-methyl-2-(chloromethylphosphate)-l,2-dicarbadodecaborane (6) were synthesized by the. methods described in the literature/15/. Closo-l,2-C2BoH2 (ocarborane), closo-l-Ph-l,2-C2BoHl (phenyl-o-carborane), and closo-l-Me-l,2-C2BoH (methyl-ocarborane) were obtained from KATCHEM and used as received. N6-3'-O-dibenzoyl-2'-deoxyadenosine, N 2-isobutyryl-3'-acetyl-2'-deoxyguanosine, phenyl dichlorophosphine and methyl dichlorophosphate were obtained from Sigma-Aldrich and used without further purification. Tetrahydrofuran (THF), triethylamine (TEA) were dried over sodium metal and benzophenone and doubly distilled before use.
Spectroscopic and analytical procedures
The tH, B, 3tp and t3C NMR spectra were recorded on a Bruker Fourier-transform multinuclear NMR spectrometer at 200, 64.2, 80.2 and 50.3 MHz, respectively. Infrared spectra were recorded using a Nicolet Magna 550 FT-IR spectrophotometer with OMNIC software. Elemental analyses were obtained in house using a Perkin Elmer 2400 CHN elemental analyzer.
Synthetic procedures
All experiments were carried out in 100 mL Pyrex glass round-bottom flasks of each fitted with a nitrogen inlet and containing a magnetic stirring bar. All known compounds among the products were identified by comparing their IR and NMR spectra and melting points with those of authentic samples.
A 0.28 mmol (0.12 g) sample of 1,2-bis(chlorophenylphosphino)-1,2-dicarbadodecaborane (!), N6-3'-Odibenzoyl-2'-deoxyadenosine (0.56 mmol, 0.26 g), and triethylamine (0.58 mmol, 0.057 g) was dissolved in anhydrous THF in an inert atmosphere and the mixture was stirred for 10 h. After removing the insoluble materials by filtration, the solvent in the filtrate was removed under reduced pressure and the resulting residue was dissolved in chloroform (30 mL) and washed with water (3 x 20 mL) in an extraction procedure. The 
In an inert atmosphere, a 0.28 mmol (0.12 g) sample of 1,2-bis(chlorophenylphosphino)-l,2-dicarbadodecaborane (1), N2-isobutyryl-3'-acetyl-2'-deoxyguanosine (0.57 retool, 0.21 g), and triethylamine (0.59 retool, 0.057 g) were dissolved in anhydrous THF and the mixture was stirred for 18 h. After removing the insoluble materials by filtration, the solvent in the filtrate was removed under reduced pressure and the resulting residue was extracted with chloroform (25 mL) and washed with water (3 x 15 mL). The organic layer in the extract was dried over MgSO4, filtered and concentrated under reduced pressure to produce a solid residue that was purified by column chromatography, using silica gel and a solvent mixture of ethyl acetate: hexane" pentane (7:2:1) as an eluent, to isolate b as an off-white solid in 58 % yield (0.162 retool, 0.17 g). M. P. >200 C dec. Spectroscopic and Analytical Data: H NMR (DMSO, relative to Me4Si) 6 
In a procedure identical to that described above for a and b, the reaction involving 0.28 mmol (0.10 g) 
In a procedure identical to that described above for a and b, the reaction of 0.28 mmol (0.10 g) of l- 
In a procedure identical to that described above, the reaction of 0.43 mmol (0. 
In a procedure identical to that described above, the reaction involving 0.43 mmol (0.13 g) of l-methyl-2-(chlorophenylphosphino)-l,2-dicarbadodecaborane (3) with N2-isobutyryi-3'-acetyl-2'-deoxyguanosine ( 
2-Bis[methylphsphate-N6-3--dibenzyl-2-dexyadensine]-2-dicarbaddecabrane (4a)
In a procedure identical to that described above, the reaction of 0.35 mmol (0.13 g) of 1,2-bis 
In a procedure identical to that described above, the reaction of 0.36 mmol (0.12 g) of l-phenyl-2- 
In a procedure identical to that described above, the reaction of 0.36 mmol (0.12 g) of I-phenyl-2- 
In a procedure identical to that described above, the reaction of 0.29 mmol (0.08 g) of 1-methyl-2- 
RESULTS AND DISCUSSION
We recently reported the synthesis of carboranyl bis(adenosine diphosphate) (CBADP) in which diphosphorylated adenosine base was attached to both the carbons of the carborane cage. The specific synthetic route involved the reaction of 1,2-bis(methyl dichlorophosphate)-1,2-dicarbadodecaborane with 5'-methoxy monophosphorylated-3'-O-and N6-protected deoxyadenosine /13/. However, the present work involves the syntheses of a number of carboranyl nucleosides in which the phosphino or phosphate substituted bases are attached either to one carbon or both the carbons of the carborane cage, instead of the diphosphorylated bases. In addition, the present work has been performed with two bases (adenosine and guanosine). The synthetic route has been simplified by one step reaction involving the chlorophenylphosphino-substituted and chioromethylphosphate-substituted carboranes with adenosine or guanosine to yield the desired species, la-6b as shown in Schemes I-2.
1,2-Bis[phenylphosphinodeoxynucleoside]-l,2-dicarbadodecaborane, la-b, and l-phenyl or methyl-2-[phenylphosphinodeoxynucleoside]-l,2-dicarbadodecaborane, 2a-b or 3a-b, were obtained in moderate yields (56-62 %) from the reaction of 3'-0-and N6-protected deoxyadenosine, or from similarly protected deoxyguanosine, with the disubstituted (phenylchlorophosphine)carborane or the monosubstituted (phenylchlorophosphine)methyl-or phenyl carborane with triethylamine in THF. Protection of the base nitrogens in deoxyadenosine and deoxyguanosine was also important to prevent boronation at the base positions. All of the carboranyl derivatives of mono-and diphosphites and phosphonates have been characterized by their elemental analyses, NMR spectra and IR spectra. The 31p NMR resonance was observed between 7.00-8.25 ppm as a broad singlet, presumably due to a long-range coupling of the phosphorus with the boron atoms of the cage. it is of interest to note that the 3p chemical shifts for a number of closo-o-carboranylphosphines appear in the range of 5.4 ppm to 54.2 ppm depending on the substituent on the phosphorus atom/16/. On the other hand, the B NMR chemical shifts of closo-o-carboranylphosphines appear in the range of-! ppm to -13 ppm/16/, and are almost similar to those of la 3b whose B NMR chemical shifts appeared in the range of-2.00 to-16.00 ppm indicating the presence of similar cage functionality on the cage carbons in these compounds. The The compounds 1,2-bis[methylphosphatedeoxynucleoside]-l,2-dicarbadodeca-borane, 4a-b, and l-phenyl or methyl-2-[methylphosphatedeoxy-nucleoside]-l,2-dicarbadodecaborane, 5a-b or 6a-b, were obtained in 50-58 % yield from the reaction of the appropriate deoxynucleoside and the disubstituted (chloromethylphosphate), or the mono-substituted (chloromethylphosphate) carborane. The deprotection of the protecting groups on the bases in the final compounds was not tried. All of the products shown in Scheme 2 have been characterized by elemental analyses, H, B, 3C and P NMR spectra and IR spectra (see Experimental section). The chemical shift values of 6 8.25 ppm in the 3P NMR spectra, 6 -2.61 to-16.38 ppm in the B NMR spectra, and 6 71.0 83.6 ppm in the C NMR spectra, in addition to those in the H NMR spectra, are all in the range observed for the recently reported carboranyl bis(adenosine diphosphate) /13/ indicating the presence of similar linkages that exist between the exo-polyhedral moieties and the closo-o-carboranyl cage in 4a-b, 5a-b and 6a-b. The IR spectra showed the characteristic B-H stretching frequencies in the region of 2565-2580 cm-. Nonetheless, the utility of these compounds as a tumor-targeting species for effective boron neutron capture therapy (BNCT) or in photodynamic therapy (PDT) will be investigated in the near future. Since all of the reaction sequences, described in Schemes 1-2, are of a general nature, they represent a blueprint for the synthesis of a family of potentially valuable hydrolytically stable carborane nucleic acid constructs. Studies evaluating the in-vitro and in-vivo localizing ability of these novel compounds are currently being carried out in our laboratories. 
